SRX3177

SRX3177 is an inhibitor of CDK and CDK4 and related targets used in studies of PI3K-Akt-mTOR Signaling and Cell Cycle Regulation. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to growth-factor signaling, survival control, and nutrient-sensing outputs and checkpoint control, mitotic progression, and proliferation timing in cancer, cell cycle, and cell signaling models.

By inhibiting CDK and CDK4 and related targets, SRX3177 can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and checkpoint control, mitotic progression, and proliferation timing. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CDK and CDK4 and related targets
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and Cell Cycle Regulation
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, SRX3177 is appropriate when a defined chemical perturbant is needed to connect CDK and CDK4 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.